# Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

> **NCT05244577** · PHASE3 · UNKNOWN · sponsor: **Shi Yanxia** · enrollment: 75 (estimated)

## Conditions studied

- Olanzapine
- CINV
- Testicular Cancer by AJCC V6 and V7 Stage
- Cisplatin

## Interventions

- **DRUG:** Olanzapine Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05244577
- **Lead sponsor:** Shi Yanxia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-18
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05244577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05244577, "Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05244577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*